Active — Not RecruitingPhase 4

Immunogenicity of HPV Vaccine in Transplant Recipients.

United States30 participantsStarted 2023-06-01

Plain-language summary

To measure levels of HPV antibodies in post-solid-organ transplant recipients who have gotten the HPV9 vaccine.

Age range18 Years – 45 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Patient between the age of 18 and 45 years
✓. Patient is at least 6 months post-solid-organ transplant and has not received GARDASIL 9.
✓. Patient who can participate in their health care and sign informed consent.
✓. Patient may have had bivalent or quadrivalent HPV vaccination previously.
✓. Living or deceased donor transplant patient is eligible.

✕. Contraindication: Hypersensitivity, including severe allergic reactions to yeast (a vaccine component), or after a previous dose of GARDASIL 9 or GARDASIL.
✕. Patient had completed vaccination series with a nonavalent HPV vaccine (e.g., GARDASIL 9) in the past
✕. Patient with a diagnosis of HIV.
✕. Patient that endorses being currently pregnant.

Primary Outcome

Timeframe: 7 months, 12 months and 24 months

NCT IDNCT05557370

SponsorMedical College of Wisconsin

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2028-12-31